TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants with P. falciparum infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Revised Children's Anxiety and Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anti-Xa assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in The Shoulder Pain and Disability Index (SPADI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Range Of Motion (ROM) Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioimpedance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new infections since start of dialysis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fatigue interference score at one week
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in fatigue interference score at three months
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in health-related quality of life score at one week
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in health-related quality of life score at three months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efferocytosis Index (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Milvexian at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24hours]) of Milvexian at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Atorvastatin at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24hours]) of Atorvastatin in Healthy Participants at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyclosporine AUC0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALXN2050 AUC0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tacrolimus AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM Time Below 54 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CGM Time Above 180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Numerical Rating Scale [NRS] (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory-Short Form (Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Emotional Distress - Short Form (Change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of children hospitalized for Rhinovirus-infection
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of ATTR with AVi <0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of ATTR with AVi ≥0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of treatment-associated moderate and severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reward prediction errors (PEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Valence prediction errors (PEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arousal prediction errors (PEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clot Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clot Strength/Firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: STAR Excursion test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Fall Efficacy scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of conduction gaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of atrial fibrillation/tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of children who become corrected post operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children with post operative residual squint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilateral Comparison Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multimodal Functional Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression pattern of CD19 complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Primary Care visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Evaluate preliminary antitumor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in The Revised Children's Anxiety and Depression Scale (RCADS-25) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of randomly assigned patients who completed study period and 90-day follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with completed CRP and daily bowel movements recorded on Day 2 or Day 3 prior to sequentially randomized allocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who successfully underwent the second randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of MRD negative patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Description of microbiomes from bronchoalveolar fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Description of microbiomes from nasopharyngeal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Description of microbiomes from sputum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in DOMS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical activity pattern
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite Safety Endpoint (CSE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change from baseline in gut permeability marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change from baseline in intestinal inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change from baseline in vagally mediated Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in participants' skin conductance response (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in the prefrontal cortex measured with fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the amygdala measured with fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the hippocampus measured with fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in nicotine beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in methylation of OXTR receptor gene rs53576
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Beck Depression Inventory, Second Edition (BDI-II) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes Postpartum Depression Screening Scale (PDSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Dyadic Adjustment Scale (DAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence level to lung protective ventilation strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of all falls (non-injurious and injurious)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of newly diagnosed malignancy, hematologic disorder, and/or autoimmune or rheumatologic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline over time in hemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline over time in platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of interventions performed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance Based Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disease and rejection free survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of clinical, sickle cell adverse events (grade ≥ 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of non-SCA related adverse events (grade ≥3), including death
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of fecal calprotectin lab measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of global undernutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of the AMSE tool in identifying ASD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hip Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of home RRT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cardiovascular Disease Risk Awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Loneliness levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Investigator Global Assessment of 0 or 1 at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with positive anti-SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dmean to the pelvic bones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean V15Gy to the bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brain-derived neurotrophic (BDNF) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tolerability of the intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain assessed by visual numeric scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Early Warning System (PEWS) calculated by parent using smartphone app
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Early Warning System calculated by nurse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Earthquake Trauma Level Determination Scale (PETLDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Earthquake Stress Coping Strategies Scale (ESCSS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of impression technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success at 12 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inappropriate ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity and specificity of cfDNA methylation-based detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Anxiety at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impact on bacterial vaginosis (BV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent of participants with immediate solicited adverse events (AEs), serious adverse events (SAEs) at least 30 minutes after each study vaccine administration
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of participants with solicited AEs, SAEs within 7 days after each study vaccine administration
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of participants with unsolicited AEs, SAEs until 28 days after the last primary dose
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects who tolerate subcutaneous injections and are compliant with self-administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants who remain free of biopsy-proven acute T-cell mediated rejection (aTCMR) or antibody-mediated rejection (ABMR)
Endpoint domain: Mortality/survival
Primary endpoint: Rectum preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Particle size of food bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Adult ADHD Investigator Symptom Rating Scale (AISRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5-Expanded (DSM-5 ASRS Expanded)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Behavioral Rating Inventory of Executive Function- Adult Version (BRIEF-A) Self-report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum urinary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Pearlin Caregiver Stress Scales score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in State-Trait Anxiety Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Caregiver Burden Index
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Participant perceived compassion and understanding by the group therapy provider
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients' self-reported psychological flexibility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physician and psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Score of Food Allergy Quality of Life-Parent Burden Questionnaire (FAQL-PB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of muscularis propria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of inconclusive pathology
Endpoint domain: Adverse events/effects
Primary endpoint: Expression of MFI2-AS1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target registration errors between US reconstructions and ground truth CT data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pedicle screw placement - Trajectory errors in terms of position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pedicle screw placement - Trajectory errors in terms of direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Programmed Death Cell Ligand 1 (PD-L1) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in average haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in functional autonomy (frailty)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bacterial plaque indicator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Acceptance Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spermatozoa count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Spermatozoa progressive motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in hand grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in The five-repetition sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in six-meter walking speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Skeletal muscle mass index (SMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Immunophenotyping results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of mNGS compared to standard pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of mNGS compared to standard pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of agreement between mNGS and standard pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to successful clinical recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Stringent Complete Response (sCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate Vigorous Physical Activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in mean SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coefficient of antagonist activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overactive Bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of (serious) adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of device deficiency
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement performance of fine motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement performance of general motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of oculomotricity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Epworth Sleepiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Migraine Disability Assessment Test score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Work rate adjustments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface and marginal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal adaptation and discoloration of the materials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Acceptability/Adherence Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic performance of Time To Peak parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Articulated Thoughts of Barriers to Bystander Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Articulated Thoughts of Intentions to Intervene as a Bystander
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Volume reduction of the limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes